POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for myelofibrosis: experimental drug combo tested in japan
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug pelabresib to the standard treatment ruxolitinib is safe for Japanese adults with myelofibrosis, a rare bone marrow cancer. Only 6 participants will receive the combination to check for side effects and how the dru…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC